Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 12 April 2021, 12:16 HKT/SGT

Source: Eisai
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021

TOKYO, Apr 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its animation "Leave No One Behind-Disease of Neglected People" which features activities for the elimination of lymphatic filariasis (LF) has received the Animation Award at the International Society for Neglected Tropical Diseases (ISNTD) Festival 2021.

ISNTD Festival is an annual event aiming to increase awareness about neglected tropical diseases (NTDs) and this year marks the 5th ISNTD Festival. At the ISNTD Festival Awards, which accompanies this festival, outstanding projects will be selected and awarded in each of the seven categories of animation, app, art, awareness campaign, mass media, photo, and video, related to NTDs.

The award-winning animation "Leave No One Behind" features the 10-year LF elimination activities of Eisai and its global partners which have been implemented since Eisai signed a joint statement with the World Health Organization (WHO) for the LF elimination in 2010. The animation highlights the feelings, thoughts and sufferings of patients which were perceived through activities for free provision of medicines and disease awareness. In addition, the animation highlights tremendous efforts of global partners including Eisai dedicated for drug delivery to remote regions, disease awareness activities for residents in endemic regions and support for mass drug administrations (MDAs), in order to make necessary medicines available to those who need them.

Eisai has been manufacturing diethylcarbamazine (DEC tablets), one of the LF treatments, at its Vizag Plant in India and has been providing to LF endemic countries for free since 2013. We have provided 2.01 billion DEC tablets to 28 countries and contributed to LF elimination in Egypt, Kiribati, Thailand and Sri Lanka. We have also been collaborating with global partners on disease awareness for LF and support for implementation of MDAs necessary for the LF elimination. Eisai announced to continue providing DEC tablets for free to endemic countries that need DEC until LF is eliminated in these countries.

By accelerating the development of new medicines for infectious diseases and NTDs including LF which are endemic in developing and emerging countries via leveraging partnerships, together with implementing activities to improve access to medicines including raising disease awareness locally and implementing price setting models that take income levels into account, Eisai strives to further contribute to increasing the benefits for patients and their families worldwide.

Media Inquiries:
Public Relations Department
Eisai Co., Ltd.

Topic: Press release summary
Source: Eisai

Sectors: BioTech
From the Asia Corporate News Network

Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Oct 18, 2021 08:00 HKT/SGT
Eisai and Merck & Co., Inc. (Kenilworth, N.J.) Receive Positive EU CHMP Opinions for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Two Different Types of Cancer
Sept 28, 2021 10:37 HKT/SGT
Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the Accelerated Approval Pathway
Sept 27, 2021 13:50 HKT/SGT
Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval
Sept 14, 2021 16:46 HKT/SGT
Eisai to Join The Global Environmental Initiative "RE100"
Sept 14, 2021 11:36 HKT/SGT
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021
Sept 13, 2021 15:37 HKT/SGT
AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Service for Patients"
Aug 31, 2021 08:42 HKT/SGT
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries
Aug 16, 2021 09:07 HKT/SGT
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Launched in Japan for EZH2 Gene Mutation-Positive Follicular Lymphoma
Aug 12, 2021 08:31 HKT/SGT
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC)
Aug 5, 2021 10:45 HKT/SGT
Eisai Receives Award for Excellence in Corporate Communications at the 37th Corporate Communications Awards
More news >>
 News Alerts
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: